{"id":72502,"date":"2026-08-14T12:15:46","date_gmt":"2026-08-14T04:15:46","guid":{"rendered":"https:\/\/flcube.com\/?p=72502"},"modified":"2026-08-14T12:15:46","modified_gmt":"2026-08-14T04:15:46","slug":"cde-adds-two-new-drugs-to-rare-disease-caring-program-extension-pilot-szj0107-and-jab-8263-included","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72502","title":{"rendered":"CDE Adds Two New Drugs to Rare Disease &#8220;Caring Program \u2013 Extension&#8221; Pilot \u2013 SZJ0107 and JAB-8263 Included"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">According to the latest announcement from the <strong>Center for Drug Evaluation (CDE)<\/strong> of the <strong>National Medical Products Administration (NMPA)<\/strong>, two new drugs have been included in the <strong>&#8220;Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases (&#8216;Caring Program \u2013 Extension&#8217;)&#8221;<\/strong>: <strong>SZJ0107 tablets<\/strong> by <strong>Anhui Sanzhijian Pharmaceutical Technology Co., Ltd.<\/strong> for the treatment of <strong>spinocerebellar ataxia<\/strong>, and <strong>JAB-8263 tablets<\/strong> by <strong>Beijing Jacobio Pharmaceuticals Group Co., Ltd.<\/strong> (HKG: <strong>1167<\/strong>) for the treatment of <strong>myelofibrosis<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-program-inclusion-snapshot\" class=\"wp-block-heading\">Program Inclusion Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>SZJ0107<\/th><th>JAB-8263<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsor<\/strong><\/td><td>Anhui Sanzhijian Pharmaceutical Technology Co., Ltd.<\/td><td>Beijing Jacobio Pharmaceuticals Group Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1167:HKG\">HKG: 1167<\/a>)<\/td><\/tr><tr><td><strong>Formulation<\/strong><\/td><td>Tablets<\/td><td>Tablets<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Spinocerebellar ataxia<\/td><td>Myelofibrosis<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Not yet disclosed<\/td><td><strong>BET inhibitor<\/strong><\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Clinical trial application stage<\/td><td>Phase I completed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-szj0107\" class=\"wp-block-heading\">Drug Profile \u2013 SZJ0107<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sponsor:<\/strong> <strong>Anhui Sanzhijian Pharmaceutical Technology Co., Ltd.<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Spinocerebellar ataxia<\/strong>, a rare, progressive neurodegenerative disorder<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> The target and mechanism of <strong>SZJ0107<\/strong> have not yet been disclosed<\/li>\n\n\n\n<li><strong>Status:<\/strong> Currently at the <strong>clinical trial application stage<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-evidence-jab-8263\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Evidence \u2013 JAB-8263<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sponsor:<\/strong> <strong>Beijing Jacobio Pharmaceuticals Group Co., Ltd.<\/strong> (HKG: <strong>1167<\/strong>)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> <strong>JAB-8263<\/strong> is a <strong>BET inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Myelofibrosis<\/strong>, a rare hematologic malignancy<\/li>\n\n\n\n<li><strong>Phase I Readout:<\/strong><\/li>\n\n\n\n<li><strong>Well\u2011tolerated<\/strong> in Phase I clinical trials<\/li>\n\n\n\n<li>As a <strong>monotherapy<\/strong>, can induce <strong>spleen volume reduction (SVR)<\/strong> in the majority of patients with myelofibrosis<\/li>\n\n\n\n<li>Improves <strong>total symptom score (TSS)<\/strong> in the majority of patients<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Policy Support for Rare Disease Innovation:<\/strong> Inclusion in the <strong>CDE<\/strong> &#8220;Caring Program \u2013 Extension&#8221; signals regulatory encouragement for innovative drugs targeting rare diseases, potentially offering development incentives and expedited pathways under the <strong>NMPA<\/strong> framework.<\/li>\n\n\n\n<li><strong>Unmet Needs in Two Rare Conditions:<\/strong> <strong>Spinocerebellar ataxia<\/strong> and <strong>myelofibrosis<\/strong> both carry significant unmet medical needs, with limited approved treatment options globally.<\/li>\n\n\n\n<li><strong>JAB-8263 Early Momentum:<\/strong> The Phase I profile \u2014 tolerability plus SVR and TSS improvements as monotherapy \u2014 provides early differentiation signals in myelofibrosis, a space where combination strategies and novel mechanisms are actively pursued.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Mechanism disclosure and trial progression for <strong>SZJ0107<\/strong>, and the Phase II design for <strong>JAB-8263<\/strong>, will be the next catalysts for both programs.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the clinical development of SZJ0107 and JAB-8263, regulatory proceedings under the Caring Program \u2013 Extension pilot, and potential therapeutic applications. Actual results may differ due to risks including clinical outcomes, regulatory requirements, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>According to the latest announcement from the Center for Drug Evaluation (CDE) of the National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[102,895,154,14,24,4899],"class_list":["post-72502","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cde","tag-hkg-1167","tag-jacobio-pharmaceuticals","tag-nmpa","tag-rare-orphan-disease-drugs","tag-sanzhijian-pharmaceutical-technology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CDE Adds Two New Drugs to Rare Disease &quot;Caring Program \u2013 Extension&quot; Pilot \u2013 SZJ0107 and JAB-8263 Included - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"According to the latest announcement from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), two new drugs have been included in the &quot;Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases (&#039;Caring Program \u2013 Extension&#039;)&quot;: SZJ0107 tablets by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd. for the treatment of spinocerebellar ataxia, and JAB-8263 tablets by Beijing Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) for the treatment of myelofibrosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72502\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CDE Adds Two New Drugs to Rare Disease &quot;Caring Program \u2013 Extension&quot; Pilot \u2013 SZJ0107 and JAB-8263 Included\" \/>\n<meta property=\"og:description\" content=\"According to the latest announcement from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), two new drugs have been included in the &quot;Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases (&#039;Caring Program \u2013 Extension&#039;)&quot;: SZJ0107 tablets by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd. for the treatment of spinocerebellar ataxia, and JAB-8263 tablets by Beijing Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) for the treatment of myelofibrosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72502\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-14T04:15:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72502#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72502\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CDE Adds Two New Drugs to Rare Disease &#8220;Caring Program \u2013 Extension&#8221; Pilot \u2013 SZJ0107 and JAB-8263 Included\",\"datePublished\":\"2026-08-14T04:15:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72502\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CDE\",\"HKG: 1167\",\"Jacobio Pharmaceuticals\",\"NMPA\",\"Rare \\\/ orphan disease drugs\",\"Sanzhijian Pharmaceutical Technology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72502#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72502\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72502\",\"name\":\"CDE Adds Two New Drugs to Rare Disease \\\"Caring Program \u2013 Extension\\\" Pilot \u2013 SZJ0107 and JAB-8263 Included - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-14T04:15:46+00:00\",\"description\":\"According to the latest announcement from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), two new drugs have been included in the \\\"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program \u2013 Extension')\\\": SZJ0107 tablets by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd. for the treatment of spinocerebellar ataxia, and JAB-8263 tablets by Beijing Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) for the treatment of myelofibrosis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72502#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72502\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72502#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CDE Adds Two New Drugs to Rare Disease &#8220;Caring Program \u2013 Extension&#8221; Pilot \u2013 SZJ0107 and JAB-8263 Included\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CDE Adds Two New Drugs to Rare Disease \"Caring Program \u2013 Extension\" Pilot \u2013 SZJ0107 and JAB-8263 Included - Insight, China&#039;s Pharmaceutical Industry","description":"According to the latest announcement from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), two new drugs have been included in the \"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program \u2013 Extension')\": SZJ0107 tablets by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd. for the treatment of spinocerebellar ataxia, and JAB-8263 tablets by Beijing Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) for the treatment of myelofibrosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72502","og_locale":"en_US","og_type":"article","og_title":"CDE Adds Two New Drugs to Rare Disease \"Caring Program \u2013 Extension\" Pilot \u2013 SZJ0107 and JAB-8263 Included","og_description":"According to the latest announcement from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), two new drugs have been included in the \"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program \u2013 Extension')\": SZJ0107 tablets by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd. for the treatment of spinocerebellar ataxia, and JAB-8263 tablets by Beijing Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) for the treatment of myelofibrosis.","og_url":"https:\/\/flcube.com\/?p=72502","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-14T04:15:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72502#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72502"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CDE Adds Two New Drugs to Rare Disease &#8220;Caring Program \u2013 Extension&#8221; Pilot \u2013 SZJ0107 and JAB-8263 Included","datePublished":"2026-08-14T04:15:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72502"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CDE","HKG: 1167","Jacobio Pharmaceuticals","NMPA","Rare \/ orphan disease drugs","Sanzhijian Pharmaceutical Technology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72502#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72502","url":"https:\/\/flcube.com\/?p=72502","name":"CDE Adds Two New Drugs to Rare Disease \"Caring Program \u2013 Extension\" Pilot \u2013 SZJ0107 and JAB-8263 Included - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-14T04:15:46+00:00","description":"According to the latest announcement from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), two new drugs have been included in the \"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program \u2013 Extension')\": SZJ0107 tablets by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd. for the treatment of spinocerebellar ataxia, and JAB-8263 tablets by Beijing Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) for the treatment of myelofibrosis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72502#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72502"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72502#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CDE Adds Two New Drugs to Rare Disease &#8220;Caring Program \u2013 Extension&#8221; Pilot \u2013 SZJ0107 and JAB-8263 Included"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72502"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72502\/revisions"}],"predecessor-version":[{"id":72503,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72502\/revisions\/72503"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}